Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. - Wikidata - wikimedia - TriplyDB

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

http://www.wikidata.org/entity/Q33370229

about

Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges Novel delivery strategies for glioblastoma PI3K/PTEN signaling in angiogenesis and tumorigenesis Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Effect of lipid mimetics of GM3 and lyso-GM3 dimer on EGF receptor tyrosine kinase and EGF-induced signal transduction.Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies Experimental approaches for the treatment of malignant gliomas.Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.mTOR signaling in glioblastoma: lessons learned from bench to bedside.Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications.Glial progenitors as targets for transformation in glioma.Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells The challenges and the promise of molecular targeted therapy in malignant gliomas.Innovative Therapies against Human Glioblastoma Multiforme Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.Investigating mammalian target of rapamycin inhibitors for their anticancer properties.Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Inhibiting kinases in malignant gliomas.

P2860

Q21284986-4EBF659D-B1DF-422A-9721-DE3572ECEA1F Q24338526-01B85A08-A34A-4134-9A16-8A2F5CB3FA10 Q26822717-681D5D7E-19DE-4130-BEAA-1717B30F3AF3 Q26862516-3C0240A6-BEE2-43C1-A86F-AA7E202E6B92 Q27006099-3AAB323B-317D-418A-B7C0-77100E602800 Q28383083-C9DE94C3-4971-47AF-B3BF-1AA4E2332CAD Q30437740-9F22A54E-AE0B-4722-9B5D-F958C2EECCBB Q30456087-AA46526A-C56C-4643-80F2-4CF4EDD6CB39 Q33307091-8AB4AD0B-2C4F-438B-A959-39DABED540E8 Q33393707-DC98F9BB-C940-45DD-9162-63B22401FAFA Q33578960-A900A4AA-2F11-4F76-BE7A-BD810D8191EA Q33644407-3E9127EA-9738-4699-8703-1A8450F9ABEB Q33747609-8179EE15-B0B5-46AA-AEEA-52839A18E1FE Q33771160-432E5596-AFDA-4B96-A860-0306EA67F848 Q33858387-3FFDCE78-937B-4494-80A5-2D12DDF5E096 Q33872371-CD92259D-3499-4CC6-806C-E2CF7F54EA7E Q33925544-6BDCE07F-1AB6-4A93-A31B-374BE221A2CE Q34127138-7060D7D6-C9C0-41D6-BD7E-1A96E67B0D9A Q34132781-2B1366A7-F7BF-45F9-8AC0-19C8468768D8 Q34133033-1D95ABCF-D338-43AC-8ED2-565720B1D30D Q34196216-743852E0-1310-4A8F-AA4A-DDC89F8A4812 Q34363435-E2C1CE6C-F08F-474D-9CFB-0D5703E244CF Q34447846-03EDF372-594C-4BAC-A5BE-4F5908A2F2F6 Q34480689-B772ECA6-B487-432B-B2B7-4F7057D18884 Q34610495-867B5690-3AD5-4947-AE35-88D0BFC3D0C8 Q34735661-919655B8-753A-4873-9392-8CD1E4AFA832 Q34966112-240CFBBC-EFA4-4D3D-AE15-A7BEDA3E2317 Q35214534-126F0742-AC39-44DD-870F-E71655E5E33E Q35374492-CAECDF86-4C12-4081-A514-19512D911076 Q35534349-F63B2FCA-8518-4682-BD93-471371AA7267 Q35542196-BBB25E2A-97DD-419D-90D3-3A88B16115DC Q35864082-24C74809-83AF-479D-B0B7-D1695B05803C Q35914525-EC53EEED-7F52-422C-B58F-858E6D3C3345 Q36499234-2EAF1DD3-25D7-4B04-BA3A-CA73EFF4E5F2 Q36544472-75DAA701-D7CE-4D4E-A391-BE5505760D0B Q36600294-6043EE89-BE75-4886-93AF-330995531494 Q36668246-16775909-696C-4BD0-984E-27ED2D32386D Q36740744-D3749FC4-C749-4D1C-B88D-079DBF3295B4 Q36742629-BFDBC2AA-650F-4460-85BA-2BB8F727F362 Q36764876-CB667FAC-42B8-4934-AAC8-4EB0B391279B

P2860

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

http://www.wikidata.org/entity/Q33370229

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

@ast

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

@en

type

label

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

@ast

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

@en

prefLabel

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

@ast

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

@en

P1433

Q33370229-854F6EDE-EBCF-4955-8A0D-D15E152405FD

P1476

Q33370229-117620B6-2FB1-4276-8F0C-31953F0882AC

P2093

Q33370229-0BB49DD9-FE13-4504-B55F-737907E5CC0A

Q33370229-0EFCA45E-45AA-4764-854F-8EA74D41B4D2

Q33370229-31FEBBE6-C010-412F-9FB4-9E60CE095664

Q33370229-3321FC1F-65A0-43C2-8E10-B9F5D9D985A2

Q33370229-35579194-C8E8-413A-9304-73A0308ADFCB

Q33370229-37F1A493-9930-49E9-9DD3-F199842B9C67

Q33370229-4815CF48-5008-4C84-83F2-0B001DAD44B5

Q33370229-4FF6E043-E1D6-4CA6-9E68-7F772573AFE8

Q33370229-63E30428-73A4-4CA0-9BB3-B1A891B47CAC

Q33370229-9731D808-E890-4991-A6BC-D7472F71B7EE

P304

Q33370229-1B4CFCE5-6973-4A81-B542-ADA829865DF7

P31

Q33370229-E35DC977-4279-4B46-9A47-87C48AE0843E

P356

Q33370229-BCF1E107-2190-4423-B4DC-050DE80B2655

P407

Q33370229-684303CA-9D8A-4802-B8C0-12775927F0DD

P433

Q33370229-2DA919BB-8707-4913-9929-66A8D16154D1

P478

Q33370229-5893AEA1-B547-4AF4-9C4D-13F43387AEF0

P50

Q33370229-4FB2B786-B98D-43B0-95D7-D0D04F7D6465

Q33370229-5E173D23-4405-401D-94D8-FD9A9838C727

Q33370229-62BF2CA8-CDE1-4531-B139-31B93025778F

Q33370229-8286BF53-3441-4023-BFF5-6269E81277DF

Q33370229-9187D136-FDDC-4CE1-A59E-D300C9FAA552

Q33370229-C882117E-0B6B-4094-9200-2C0C9CBA3855

Q33370229-FD87081C-2D25-4771-87EF-DD340F687C31

P577

Q33370229-88F7D3D5-C2B0-42BB-B178-EA7DF4A49FE6

P698

Q33370229-FB8DCB05-C543-491A-B33C-CE2E37773E40

P921

Q33370229-3D889E57-101B-4FB2-9718-3E0D21828F84

P356

1078-0432.CCR-05-2215

P1433

Clinical Cancer Research

P1476

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

@en

P2093

Alan J Swaisland

http://www.w3.org/2001/XMLSchema#string

James E Herndon

http://www.w3.org/2001/XMLSchema#string

James J Vredenburgh

http://www.w3.org/2001/XMLSchema#string

James M Provenzale

http://www.w3.org/2001/XMLSchema#string

Jeannette M Dowell

http://www.w3.org/2001/XMLSchema#string

Jennifer A Quinn

http://www.w3.org/2001/XMLSchema#string

Jeremy N Rich

http://www.w3.org/2001/XMLSchema#string

John H Sampson

http://www.w3.org/2001/XMLSchema#string

Judith S Ochs

http://www.w3.org/2001/XMLSchema#string

Peggy Lyons

http://www.w3.org/2001/XMLSchema#string

P304

860-868

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-05-2215

http://www.w3.org/2001/XMLSchema#string

P407

P433

3 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

Henry Seth Friedman

Annick Desjardins

Sridharan Gururangan

David A Reardon

Roger E McLendon

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16467100

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial